Correlation analysis of tumor purity with clinicopathological, molecular, and imaging features in high-grade gliomas

被引:0
作者
Qing Zhou
Peng Zhang
Jiangwei Man
Bin Zhang
Caiqiang Xue
Xiaoai Ke
Junlin Zhou
机构
[1] Lanzhou University Second Hospital,Department of Radiology
[2] Lanzhou University,Second Clinical School
[3] Key Laboratory of Medical Imaging of Gansu Province,Department of Pathology
[4] Gansu International Scientific and Technological Cooperation Base of Medical Imaging Artificial Intelligence,Department of Surgery
[5] Lanzhou University Second Hospital,undefined
[6] Lanzhou University Second Hospital,undefined
来源
Neurosurgical Review | 2022年 / 45卷
关键词
High-grade gliomas; Tumor purity; Tumor microenvironment; Neuroimaging;
D O I
暂无
中图分类号
学科分类号
摘要
High-grade gliomas (HGG) have high malignancy, high heterogeneity, and a poor prognosis. Tumor purity is an intrinsic feature of the HGG microenvironment and an independent prognostic factor. The purpose of this study was to analyze the correlation of tumor purity with clinicopathological, molecular, and imaging features. We performed a retrospective analysis of 112 patients diagnosed with HGG (grades III and IV) in our center. Eleven regions of interest (ROI) were randomly selected on whole-slide images (WSI, 40 × magnification) based on HGG tissue paraffin sections and hematoxylin–eosin (H&E) staining. Of these 11 ROIs, five ROIs were visually estimated by pathologists and six ROIs were automatically analyzed using ImageJ software. Last, the average tumor purity (%) of the 11 ROIs was calculated. Correlation analysis of tumor purity with clinicopathological, molecular, and imaging features was conducted. Of the 112 patients included in the study, the mean tumor purity of HGG was 70.96%. There were differences in tumor purity between WHO grades III and IV; the tumor purity of grade IV patients (67.59%) was lower than that of grade III patients (76.00%) (p < 0.001). There were also differences in tumor purity between IDH1 mutant and wild type, and the tumor purity of IDH1 mutant patients was higher than that of IDH1 wild-type patients (p = 0.006). The average range of peritumoral edema was about 19.18 mm, and the diameter of edema, ADCmean, and ADCmin were negatively correlated with tumor purity(r =  − 0.236, r =  − 0.306, and r =  − 0.242; p < 0.05). The grade of HGG, IDH1 mutant/wild type, peritumoral edema, and ADC value were correlated with tumor purity. HGG grade, IDH1 mutant/wild type, peritumoral edema, and ADC value can predict tumor purity and indirectly reflect patient prognosis.
引用
收藏
页码:3699 / 3708
页数:9
相关论文
共 191 条
  • [1] Aran D(2015)Systematic pan-cancer analysis of tumour purity Nat Commun 6 8971-1140
  • [2] Sirota M(2017)Breast cancer histopathology image analysis pipeline for tumor purity estimation Proc IEEE Int Symp Biomed Imaging 2017 1137-898
  • [3] Butte AJ(2015)Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM Sci Rep 5 7915-795
  • [4] Azimi V(2017)A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies AJNR Am J Neuroradiol 38 890-7160
  • [5] Chang YH(2017)Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma Neuro Oncol 19 786-772
  • [6] Thibault G(2021)High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer BMC Cancer 21 1305-45
  • [7] Smith J(2020)TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment Cancer Med 9 7151-1373
  • [8] Tsujikawa T(2021)Comprehensive characterization of tumor purity and its clinical implications in gastric cancer Front Cell Dev Biol 9 782529-673
  • [9] Kukull B(2021)Malignant tumor purity reveals the driven and prognostic role of CD3E in low-grade glioma Microenvironment Front Oncol 11 676124-95
  • [10] Jensen B(2019)Improved tumor purity metrics in next-generation sequencing for clinical practice: the integrated interpretation of neoplastic cellularity and sequencing results (IINCaSe) approach Appl Immunohistochem Mol Morphol 27 764-540